ACT of TRP-1-specific CD4+ T cells was able to reject established B16.F10 melanoma tumors and increase survival in IL-15−/−RAG−/− hosts relative to RAG−/− hosts without the addition of antibodies. This evidence concerns the gene TYRP1 and melanoma.